Our FIT-Ig (Fabs-In-Tandem) technology is based on the scientific rationale to combine the functions of two parental antibodies into one single molecule. This is achieved by re-arranging the DNA sequences of two monoclonal antibodies into three constructs and co-expressing them in mammalian cells. Our unique approach requires no Fc mutation; no scFv elements; and no linker or peptide connector. The Fab-domains in each arm work “in tandem” forming a tetravalent bi-specific antibody with four active and independent antigen binding sites that fully retain the biological function of their parental antibodies. By increasing the variety of FIT-Ig molecules further, EpimAb plans to build up technical know-how and generate additional scientific insights to explore the unique features and overall capabilities of this new drug format.
EpimAb’s lead candidate, EMB-01 has shown that the FIT-Ig format can also achieve significant efficacy superior to separate antibodies as well as their open combination. Read more here.